Skip to main content

Eylea and Eylea HD

Pronunciation: EYE-lee-AH and EYE-lee-AH aitch-dee
Generic name: aflibercept ophthalmic
Brand names: Eylea, Eylea HD
Dosage forms: single-dose pre-filled syringe for ophthalmic injection, single-dose vial for ophthalmic injection.
Drug class: Anti-angiogenic ophthalmic agents

Medically reviewed by Carmen Pope, BPharm. Last updated on May 22, 2024.

What are Eylea and Eylea HD?

Eylea and Eylea HD are injectable eye preparations containing aflibercept, but Eylea HD is given a higher dose and is longer-lasting. Eylea HD is also not approved for as many indications as Eylea. They are not interchangeable.

Eylea is an injectable eye preparation that is given by a healthcare provider every one to two months that may be used to treat the following conditions:

Eylea HD is a higher-dose, longer-acting injectable form of aflibercept that only needs to be given once every 2 to 4 months after an initial dosing period. This allows patients to receive less frequent injections for similar visual gains, and anatomic improvements, without an increased risk of side effects. Eylea HD is approved to treat:

The active ingredient in Eylea injections, aflibercept, is a vascular endothelial growth factor (VEGF) inhibitor that is made from a human antibody fragment. It works by keeping new blood vessels from forming under the retina (a sensory membrane that lines the inside of the eye).

Eylea was first approved on November 18, 2011, and Eylea HD was approved on August 18, 2023. Two interchangeable biosimilars to Eylea, Opuviz and Yesafili, were approved on May 20, 2024.

Eylea and Eylea HD side effects

An Eylea injection can cause serious side effects such as allergic reactions, a serious inflammation of the eye, retinal detachments, eye infections, and an increase in eye pressure, see warnings below.

Less serious Eylea or Eylea HD side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.


You should not use Eylea or Eylea HD if you are allergic to aflibercept, Eylea, Yesafili, Opuviz, or any of the inactive ingredients in these preparations. Get emergency medical help if you have any signs of an allergic reaction to Yesafili such as hives, difficulty breathing, or swelling of your eyes, face, lips, tongue, or throat.

Do not receive an Eylea injection if you have swelling or redness inside your eyes, or any type of infection (bacterial, fungal, viral) in or around your eyes.

Call your doctor at once if you have a serious side effect such as:

There is a possibility that endophthalmitis (a serious inflammation of the intraocular fluids, usually due to infection) and retinal detachments may occur following intravitreal injections. Call your doctor at once if you have eye pain or redness, swelling or puffiness around your eyes, sensitivity to light, or sudden vision problems at any time during treatment. Arterial thromboembolic events are also possible following intravitreal VEGF inhibitor injections.

Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.

Infants with ROP may need extended periods of monitoring after injections with Eylea.

Temporary visual disturbances may occur following an intravitreal injection with Eylea or Eylea HD, or the associated eye examinations. Do not drive or operate machinery until your vision recovers.

Before using Eylea or Eylea HD

You should not receive Eylea or Eylea HD if you are allergic to aflibercept, Eylea, Yesafili, Opuviz, or any of the inactive ingredients in these preparations, or if you have:

To make sure this medicine is safe for you, tell your doctor if you:


Tell your doctor if you are pregnant or plan to become pregnant while using Eylea or Eylea HD. You may need to undertake a pregnancy test if you are a female with childbearing potential. Use effective birth control to prevent pregnancy before your first dose of this medicine. Keep using birth control during treatment and for at least 3 months after your last Eylea injection.


Do not breastfeed while you are using Eylea.

How is Eylea or Eylea HD given?

Eylea and Eylea HD are given as an injection into your eye. Your doctor will use a medicine to numb your eye before giving you the injection. You will receive this injection in your doctor's office or other clinic setting.

For a short time after your injection, your eyes will be checked periodically to make sure the injection has not caused any side effects.

Dosage for Eylea

The usual recommended dose in adults is 2mg (0.05mL) (one injection) into each affected eye.

The dosage for ROP is 0.4 mg (0.01 mL or 10 microliters) administered by intravitreal injection.

Dosage for Eylea HD

The usual recommended adult dose of Eylea HD is 8mg (0.07mL) (one injection) into each affected eye.

What happens if I miss a dose?

Call your doctor to reschedule if you miss an appointment for your Eylea or Eylea HD injection.

What happens if I overdose?

An overdose is unlikely because Eylea and Eylea HD are administered by healthcare professionals. Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid?

Eylea or Eylea HD may cause blurred vision and may impair your reactions. Avoid driving or hazardous activity until you know how this medicine will affect you.

What other drugs will affect Eylea or Eylea HD?

It is not likely that other drugs you take orally or inject will have an effect on Eylea or Eylea HD used in the eyes. However, many drugs can interact with each other. Tell your doctor about all the medicines you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.


Store Eylea and Eylea HD in the refrigerator at 2°C to 8°C (36°F to 46°F).

Do not freeze. Do not use it beyond the date stamped on the carton and container label.

Store in the original carton until time of use to protect from light.


Eylea ingredients

Active: aflibercept 40 mg/mL.

Inactive: 10 mM sodium phosphate, 40 mM sodium chloride, 0.03% polysorbate 20, and 5% sucrose with a pH of 6.2.

The single-dose glass vial is designed to deliver 0.05 mL (50 microliters) of the solution containing 2 mg of aflibercept.

Eylea does not contain an anti-microbial preservative.

Eylea HD ingredients

Active: aflibercept 114.3 mg/mL solution

Inactive: a buffer containing arginine hydrochloride (0.737 mg), histidine (0.04 mg), L-histidine hydrochloride monohydrate (0.093 mg), polysorbate 20 (0.021 mg), sucrose (3.5 mg) and water for injection with a pH of 5.8.

Eylea HD does not contain an anti-microbial preservative.

The single-dose glass vial is designed to deliver 0.07 mL (70 microliters) of the solution containing 8 mg of aflibercept.


Regeneron Pharmaceuticals, Inc.

Popular FAQ

Eylea is usually injected every 4 or 8 weeks based on your condition. Some patients with wet AMD who do well may be eligible for injections every 12 weeks after 1 year of treatment. Continue treatment as long as directed by your doctor. Eylea or Eylea HD for wet AMD may involve fewer eye injections per year compared to other wet AMD treatments.

Vabysmo (faricimab) targets vascular endothelial growth factor (VEGF) and angiopoietin-1, whereas Eylea (afibercept) targets VEGF and placental growth factor (P1GF). Both agents are used to treat conditions such as macular degeneration (AMD) and diabetic macular edema and are given by intravitreal injection (into the gel part of the eye). Continue reading

Eylea, Eylea HD, and Avastin may all be used to treat neovascular (wet) age-related macular degeneration (AMD), as injections into the eye (intravitreal injections). Both Eylea and Eylea HD are FDA-approved for this indication, but use of Avastin is off-label (not an FDA-approved indication - although it has been used for this purpose since 2005). Eylea HD is a longer acting version of Eylea. Continue reading

Anti-VEGF drugs slow the abnormal growth of blood vessels associated with certain cancers and degenerative eye conditions, such as age-related macular degeneration. Anti-VEGF stands for anti-vascular endothelial growth factor. Continue reading

Eylea and Eylea HD usually work within 3 months, with some people noticing improvements in as little as one month of treatment, depending on the condition being treated. For some conditions, it may take up to 6 months before a significant difference is seen. Continue reading

Eylea and Eylea HD injections into the eye (intravitreal) are associated with a substantial but temporary increase in blood pressure in some patients. Increases in intraocular pressure (the pressure inside the eye) have also been seen within 60 minutes of an injection of Eylea or Eylea HD. Continue reading

Eylea HD is a higher dose, longer-acting formulation of Eylea that has been approved to treat Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR). Eylea is approved to treat these conditions in addition to Macular Edema Following Retinal Vein Occlusion (RVO) and Retinopathy of Prematurity (ROP). Continue reading

Eylea patents are due to run out from 2023 to 2039; however, these should not be taken as definite dates as there are many ways drug companies can extend their patents, for example, by changing the formulation of their product. A new Eylea HD patent, US11103552B2 which relates to high concentration VEGF receptor fusion protein containing formulations, has a patent expiry date of 15 May 2039. Continue reading

Medicare usually covers costs of Eylea or Eylea HD after you meet your yearly Part B deductible. Then you will usually pay 20% of the Medicare-approved amount for the drug and any medical services. Your costs may vary depending on if you have insurance copays, coinsurance or administration fees. Continue reading

View more FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.